173nok
0,9 %
Date:2025-05-14Time:16:16:17Latest report:Q4-2023List:Oslo BorsTicker:BGBIO
Market Cap:68 mnokEnterprise Value:-72 mnokNet Sales:0,85 mnokEarnings:-139,3 mnokEmployees:0ISIN:NO0013251173

Ratios

10-year key figure history for BerGenBio turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for BerGenBio with index and moving average MA50 and MA200.

Stockprice:1,73
MA50:1,70
MA200:7,43
Price/MA200:-76,7 %
RSI (14):50,8
Price/MA50:2,0 %

Description

BerGenBio is a Norwegian oncology company. The company conducts research and development of inhibitory drugs for the treatment of aggressive cancers. The company has developed a number of products whose composition intends to block the protein AXL, a protein positively related to the spread of cancer cells. The company was founded in 2007 and is headquartered in Bergen.

Biotechnology